Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hydroquinone skin bleaches

This article was originally published in The Tan Sheet

Executive Summary

NDMA requests FDA feedback meeting to discuss ongoing industry-sponsored research on the safety of hydroquinone- containing skin lighteners in a Jan. 4 letter to the agency. The letter accompanies research data and dermatologist survey data that NDMA said support the conclusions that: "hydroquinone in OTC skin lightening preparations does not present a carcinogenic risk when used according to label directions"; and "ochronosis is a rarely reported event and there are no scientific data to specifically point to currently marketed OTC hydroquinone- containing preparations as causes of exogenous ochronosis." FDA said at an industry symposium in October that hydroquinone will "probably" become nonmonograph ("The Tan Sheet" Oct. 18, In Brief)...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS082351

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel